A promising medication, Retatrutide , is generating significant attention within the weight-loss community as a potential approach for obesity . Designed by Eli Lilly , it’s a twin GIP and GLP-1 target agonist, meaning it works on two distinct pathways to regulate appetite and encourage fat utili